Herpesviruses: Hijacking the Ras signaling pathway

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1803, Issue 7, 2010, Pages 777-785

  Filippakis, Harilaos ^a   Spandidos, Demetrios A ^a   Sourvinos, George ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Cancer; EBV; HCMV; Herpesvirus; HHV6; HHV7; HHV8; HSV 1; HSV 2; Ras; VZV

Indexed keywords

GUANINE NUCLEOTIDE DISSOCIATION STIMULATOR; PHOSPHATIDYLINOSITOL 3 KINASE; RAF PROTEIN; RAL PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

APOPTOSIS; CARCINOGENESIS; CELL COMMUNICATION; CELL CYCLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL ONCOGENE; CELL PROLIFERATION; CELL SURVIVAL; DNA REPAIR; DRUG TARGETING; GAMMAHERPESVIRINAE; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GROWTH REGULATION; HERPES VIRUS; HERPES VIRUS INFECTION; HOST CELL; LATENT VIRUS INFECTION; MEDICAL RESEARCH; METASTASIS; NEOPLASM; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; TUMOR GROWTH; VIRUS CARCINOGENESIS; VIRUS REACTIVATION; VIRUS REPLICATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HERPESVIRIDAE; HUMANS; NEOPLASMS; RAS PROTEINS; SIGNAL TRANSDUCTION;

HERPESVIRIDAE; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; HUMAN HERPESVIRUS 3; HUMAN HERPESVIRUS 4;

EID: 77953479971     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2010.03.007     Document Type: Review

References (144)

1. Spandidos D.A., Sourvinos G., Tsatsanis C., Zafiropoulos A. Normal ras genes: their onco-suppressor and pro-apoptotic functions. Int. J. Oncol. 2002, 21:237-241.
2. Kiaris H., Spandidos D.A. Mutations of ras genes in human tumors. Int. J. Oncol. 1995, 7:413-421.
3. Malumbres M., Barbacid M. RAS oncogenes: the first 30years. Nat. Rev. Cancer 2003, 3:459-465.
4. Zachos G., Spandidos D.A. Transcriptional regulation of the c-H-ras1 gene by the P53 protein is implicated in the development of human endometrial and ovarian tumours. Oncogene 1998, 16:3013-3017.
5. Donovan S., Shannon K.M., Bollag G. GTPase activating proteins: critical regulators of intracellular signaling. Biochim. Biophys. Acta 2002, 1602:23-45.
6. Boguski M.S., McCormick F. Proteins regulating Ras and its relatives. Nature 1993, 366:643-654.
7. Rajalingam K., Schreck R., Rapp U.R., Albert S. Ras oncogenes and their downstream targets. Biochim. Biophys. Acta 2007, 1773:1177-1195.
8. Mitin N., Rossman K.L., Der C.J. Signaling interplay in Ras superfamily function. Curr. Biol. 2005, 15:R563-574.
9. Repasky G.A., Chenette E.J., Der C.J. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?. Trends Cell Biol. 2004, 14:639-647.
10. Moodie S.A., Willumsen B.M., Weber M.J., Wolfman A. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 1993, 260:1658-1661.
11. Warne P.H., Viciana P.R., Downward J. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature 1993, 364:352-355.
12. Zhang X.F., Settleman J., Kyriakis J.M., Takeuchi-Suzuki E., Elledge S.J., Marshall M.S., Bruder J.T., Rapp U.R., Avruch J. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature 1993, 364:308-313.
13. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298:1911-1912.
14. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 2006, 118:3030-3044.
15. Burke F., Relf M., Negus R., Balkwill F. A cytokine profile of normal and malignant ovary. Cytokine 1996, 8:578-585.
16. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
17. Surh Y.J., Chun K.S., Cha H.H., Han S.S., Keum Y.S., Park K.K., Lee S.S. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat. Res. 2001, 480-481:243-268.
18. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007, 117:1175-1183.
19. Jarvis M.A., Nelson J.A. Mechanisms of human cytomegalovirus persistence and latency. Front Biosci. 2002, 7:d1575-1582.
20. Arthur J.L., Scarpini C.G., Connor V., Lachmann R.H., Tolkovsky A.M., Efstathiou S. Herpes simplex virus type 1 promoter activity during latency establishment, maintenance, and reactivation in primary dorsal root neurons in vitro. J. Virol. 2001, 75:3885-3895.
21. Hunter T. Cooperation between oncogenes. Cell 1991, 64:249-270.
22. Yokota J., Sugimura T. Multiple steps in carcinogenesis involving alterations of multiple tumor suppressor genes. FASEB J. 1993, 7:920-925.
23. Everett R.D., Chelbi-Alix M.K. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 2007, 89:819-830.
24. Nguyen M.L., Blaho J.A. Apoptosis during herpes simplex virus infection. Adv. Virus Res. 2007, 69:67-97.
25. Reske A., Pollara G., Krummenacher C., Chain B.M., Katz D.R. Understanding HSV-1 entry glycoproteins. Rev. Med. Virol. 2007, 17:205-215.
26. Matis J., Kudelova M. Early shutoff of host protein synthesis in cells infected with herpes simplex viruses. Acta Virol. 2001, 45:269-277.
27. Taylor T.J., Brockman M.A., McNamee E.E., Knipe D.M. Herpes simplex virus. Front Biosci. 2002, 7:d752-764.
28. Kirn D.H. Replicating oncolytic viruses: an overview. Expert Opin. Investig. Drugs 1996, 5:753-762.
29. Stanziale S.F., Petrowsky H., Adusumilli P.S., Ben-Porat L., Gonen M., Fong Y. Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity. Clin. Cancer Res. 2004, 10:3225-3232.
30. Nakamura H., Kasuya H., Mullen J.T., Yoon S.S., Pawlik T.M., Chandrasekhar S., Donahue J.M., Chiocca E.A., Chung R.Y., Tanabe K.K. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J. Clin. Invest. 2002, 109:871-882.
31. Paludan S.R., Mogensen S.C. Virus-cell interactions regulating induction of tumor necrosis factor alpha production in macrophages infected with herpes simplex virus. J. Virol. 2001, 75:10170-10178.
32. Everett R.D., Rechter S., Papior P., Tavalai N., Stamminger T., Orr A. PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J. Virol. 2006, 80:7995-8005.
33. Williams B.R. PKR; a sentinel kinase for cellular stress. Oncogene 1999, 18:6112-6120.
34. He B., Gross M., Roizman B. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc. Natl. Acad Sci. U.S.A. 1997, 94:843-848.
35. Talloczy Z., Virgin H.W.t., Levine B. PKR-dependent autophagic degradation of herpes simplex virus type 1. Autophagy 2006, 2:24-29.
36. Schaffer P.A. The herpes simplex virus type 1 latency-associated transcript promoter is activated through Ras and Raf by nerve growth factor and sodium butyrate in PC12 cells. J. Virol. 1996, 70:7424-7432.
37. Frazier D.P., Cox D., Godshalk E.M., Schaffer P.A. The herpes simplex virus type 1 latency-associated transcript promoter is activated through Ras and Raf by nerve growth factor and sodium butyrate in PC12 cells. J. Virol. 1996, 70:7424-7432.
38. Wales S.Q., Li B., Laing J.M., Aurelian L. The herpes simplex virus type 2 gene ICP10PK protects from apoptosis caused by nerve growth factor deprivation through inhibition of caspase-3 activation and XIAP up-regulation. J. Neurochem. 2007, 103:365-379.
39. Aubert M.B.J.A. The herpes simplex virus type 1 regulatory protein ICP27 is required for the prevention of apoptosis in infected human cells. J. Virol. 1999, 73:2803-2813.
40. Aubert M., O'Toole J., Blaho J.A. Induction and prevention of apoptosis in human Hep-2 cells by herpes simplex virus type 1. J. Virol. 1999, 73:10359-10370.
41. Aubert M., Krantz E.M., Jerome K.R. Herpes simplex virus genes Us3, Us5, and Us12 differentially regulate cytotoxic T lymphocyte-induced cytotoxicity. Viral Immunol. 2006, 19:391-408.
42. Gillis P.A., Okagaki L.H., Rice S.A. Herpes simplex virus type 1 ICP27 induces p38 mitogen-activated protein kinase signaling and apoptosis in HeLa cells. J. Virol. 2009, 83:1767-1777.
43. Aubert M., Pomeranz L.E., Blaho J.A. Herpes simplex virus blocks apoptosis by precluding mitochondrial cytochrome c release independent of caspase activation in infected human epithelial cells. Apoptosis 2007, 12:19-35.
44. Zachos G., Koffa M., Preston C.M., Clements J.B., Conner J. Herpes simplex virus type 1 blocks the apoptotic host cell defense mechanisms that target Bcl-2 and manipulates activation of p38 mitogen-activated protein kinase to improve viral replication. J. Virol. 2001, 75:2710-2728.
45. Hunter J.C., Smith C.C., Bose D., Kulka M., Broderick R., Aurelian L. Intracellular internalization and signaling pathways triggered by the large subunit of HSV-2 ribonucleotide reductase. Virology 1995, 210:345-360.
46. Smith C.C., Luo J.H., Hunter J.C., Ordonez J.V., Aurelian L. The transmembrane domain of the large subunit of HSV-2 ribonucleotide reductase (ICP10) is required for protein kinase activity and transformation-related signaling pathways that result in ras activation. Virology 1994, 200:598-612.
47. Smith C.C., Nelson J., Aurelian L., Gober M., Goswami B.B. Ras-GAP binding and phosphorylation by herpes simplex virus type 2 RR1 PK (ICP10) and activation of the Ras/MEK/MAPK mitogenic pathway are required for timely onset of virus growth. J. Virol. 2000, 74:10417-10429.
48. Perkins D., Pereira E.F., Gober M., Yarowsky P.J., Aurelian L. The herpes simplex virus type 2 R1 protein kinase (ICP10 PK) blocks apoptosis in hippocampal neurons, involving activation of the MEK/MAPK survival pathway. J. Virol. 2002, 76:1435-1449.
49. Favata M.F., Horiuchi K.Y., Manos E.J., Daulerio A.J., Stradley D.A., Feeser W.S., Van Dyk D.E., Pitts W.J., Earl R.A., Hobbs F., Copeland R.A., Magolda R.L., Scherle P.A., Trzaskos J.M. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 1998, 273:18623-18632.
50. Lin H.J., Eviner V., Prendergast G.C., White E. Activated H-ras rescues E1A-induced apoptosis and cooperates with E1A to overcome p53-dependent growth arrest. Mol. Cell. Biol. 1995, 15:4536-4544.
51. Erhardt P., Schremser E.J., Cooper G.M. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol. Cell. Biol. 1999, 19:5308-5315.
52. Smith C.C. The herpes simplex virus type 2 protein ICP10PK: a master of versatility. Front Biosci. 2005, 10:2820-2831.
53. Guo Z.S., Thorne S.H., Bartlett D.L. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim. Biophys. Acta 2008, 1785:217-231.
54. Parato K.A., Senger D., Forsyth P.A., Bell J.C. Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer 2005, 5:965-976.
55. Fu X., Tao L., Cai R., Prigge J., Zhang X. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Mol. Ther. 2006, 13:882-890.
56. Su Y., Zhu H., Xiao W., Xu Q., Zhu L., Zhang X., Wan Q., Zhou S., Du E., Xu H., Yao L., Lv S., Hu B., Liu Y., Qi Y. Selectively oncolytic mutant of HSV-1 lyses HeLa cells mediated by Ras/RTN3. Cancer Biol. Ther. 2007, 6:202-208.
57. Farassati F., Pan W., Yamoutpour F., Henke S., Piedra M., Frahm S., Al-Tawil S., Mangrum W.I., Parada L.F., Rabkin S.D., Martuza R.L., Kurtz A. Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes. Am. J. Pathol. 2008, 173:1861-1872.
58. Fu X., Nakamori M., Tao L., Amato R., Zhang X. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma. Int. J. Oncol. 2007, 30:1561-1567.
59. Li H., Dutuor A., Fu X., Zhang X. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. J. Gene. Med. 2007, 9:161-169.
60. Li H., Dutuor A., Tao L., Fu X., Zhang X. Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin. Cancer Res. 2007, 13:316-322.
61. Fu X., Tao L., Li M., Fisher W.E., Zhang X. Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus. Clin. Cancer Res. 2006, 12:3152-3157.
62. Smith C.C., Peng T., Kulka M., Aurelian L. The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for immediate-early gene expression and virus growth. J. Virol. 1998, 72:9131-9141.
63. Pan W., Bodempudi V., Esfandyari T., Farassati F. Utilizing ras signaling pathway to direct selective replication of herpes simplex virus-1. PLoS ONE 2009, 4:e6514.
64. Gershon A.A., Sherman D.L., Zhu Z., Gabel C.A., Ambron R.T., Gershon M.D. Intracellular transport of newly synthesized varicella-zoster virus: final envelopment in the trans-Golgi network. J. Virol. 1994, 68:6372-6390.
65. Weller T.H. Varicella: historical perspective and clinical overview. J. Infect. Dis. 1996, 174(Suppl 3):S306-309.
66. Mukaida N. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am. J. Physiol. Lung Cell Mol. Physiol. 2003, 284:L566-577.
67. Desloges N., Schubert C., Wolff M.H., Rahaus M. Varicella-zoster virus infection induces the secretion of interleukin-8. Med. Microbiol. Immunol. 2008, 197:277-284.
68. Rahaus M., Desloges N., Wolff M.H. Varicella-zoster virus influences the activities of components and targets of the ERK signalling pathway. J. Gen. Virol. 2006, 87:749-758.
69. Fields B.N.T., K.L. Pathogenesis of viral infections. Fields Virol. Pathog. of Viral Infect. 2007.
70. Rahaus M., Desloges N., Wolff M.H. Replication of varicella-zoster virus is influenced by the levels of JNK/SAPK and p38/MAPK activation. J Gen Virol 2004, 85:3529-3540.
71. Sadaoka T., Yoshii H., Imazawa T., Yamanishi K., Mori Y. Deletion in open reading frame 49 of varicella-zoster virus reduces virus growth in human malignant melanoma cells but not in human embryonic fibroblasts. J. Virol. 2007, 81:12654-12665.
72. Rahaus M., Desloges N., Wolff M.H. ORF61 protein of Varicella-zoster virus influences JNK/SAPK and p38/MAPK phosphorylation. J. Med. Virol. 2005, 76:424-433.
73. Kondo K., Xu J., Mocarski E.S. Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. Proc. Natl Acad. Sci. USA 1996, 93:11137-11142.
74. Sissons J.G., Bain M., Wills M.R. Latency and reactivation of human cytomegalovirus. J. Infect. 2002, 44:73-77.
75. Streblow D.N., Nelson J.A. Models of HCMV latency and reactivation. Trends Microbiol. 2003, 11:293-295.
76. Drew W.L., Paya C.V., Emery V. Cytomegalovirus (CMV) resistance to antivirals. Am. J. Transplant. 2001, 1:307-312.
77. Doniger J., Muralidhar S., Rosenthal L.J. Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate. Clin. Microbiol. Rev. 1999, 12:367-382.
78. Cinatl J., Cinatl J., Vogel J.U., Rabenau H., Kornhuber B., Doerr H.W. Modulatory effects of human cytomegalovirus infection on malignant properties of cancer cells. Intervirology 1996, 39:259-269.
79. Cobbs C.S., Harkins L., Samanta M., Gillespie G.Y., Bharara S., King P.H., Nabors L.B., Cobbs C.G., Britt W.J. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002, 62:3347-3350.
80. Cobbs C.S., Soroceanu L., Denham S., Zhang W., Kraus M.H. Modulation of oncogenic phenotype in human glioma cells by cytomegalovirus IE1-mediated mitogenicity. Cancer Res. 2008, 68:724-730.
81. Harkins L., Volk A.L., Samanta M., Mikolaenko I., Britt W.J., Bland K.I., Cobbs C.S. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 2002, 360:1557-1563.
82. Huang G., Yan Q., Wang Z., Chen X., Zhang X., Guo Y., Li J.J. Human cytomegalovirus in neoplastic cells of Epstein-Barr virus negative Hodgkin's disease. Int. J. Oncol. 2002, 21:31-36.
83. Jarvis M.A., Wang C.E., Meyers H.L., Smith P.P., Corless C.L., Henderson G.J., Vieira J., Britt W.J., Nelson J.A. Human cytomegalovirus infection of caco-2 cells occurs at the basolateral membrane and is differentiation state dependent. J. Virol. 1999, 73:4552-4560.
84. Esclatine A., Lemullois M., Servin A.L., Quero A.M., Geniteau-Legendre M. Human cytomegalovirus infects Caco-2 intestinal epithelial cells basolaterally regardless of the differentiation state. J. Virol. 2000, 74:513-517.
85. Mitchell D.A., Xie W., Schmittling R., Learn C., Friedman A., McLendon R.E., Sampson J.H. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro. Oncol. 2008, 10:10-18.
86. Cinatl J., Scholz M., Kotchetkov R., Vogel J.U., Doerr H.W. Molecular mechanisms of the modulatory effects of HCMV infection in tumor cell biology. Trends Mol. Med. 2004, 10:19-23.
87. Wang X., Huang D.Y., Huong S.M., Huang E.S. Integrin alphavbeta3 is a coreceptor for human cytomegalovirus. Nat. Med. 2005, 11:515-521.
88. Feire A.L., Koss H., Compton T. Cellular integrins function as entry receptors for human cytomegalovirus via a highly conserved disintegrin-like domain. Proc. Natl Acad. Sci. USA 2004, 101:15470-15475.
89. Wang X., Huong S.M., Chiu M.L., Raab-Traub N., Huang E.S. Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature 2003, 424:456-461.
90. Cobbs C.S., Soroceanu L., Denham S., Zhang W., Britt W.J., Pieper R., Kraus M.H. Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness. J. Neurooncol. 2007, 85:271-280.
91. Isaacson M.K., Feire A.L., Compton T. Epidermal growth factor receptor is not required for human cytomegalovirus entry or signaling. J. Virol. 2007, 81:6241-6247.
92. Soroceanu L., Akhavan A., Cobbs C.S. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 2008, 455:391-395.
93. Reinhardt B., Mertens T., Mayr-Beyrle U., Frank H., Luske A., Schierling K., Waltenberger J. HCMV infection of human vascular smooth muscle cells leads to enhanced expression of functionally intact PDGF beta-receptor. Cardiovasc. Res. 2005, 67:151-160.
94. Zhou Y.F., Yu Z.X., Wanishsawad C., Shou M., Epstein S.E. The immediate early gene products of human cytomegalovirus increase vascular smooth muscle cell migration, proliferation, and expression of PDGF beta-receptor. Biochem. Biophys. Res. Commun. 1999, 256:608-613.
95. Boyle K.A., Pietropaolo R.L., Compton T. Engagement of the cellular receptor for glycoprotein B of human cytomegalovirus activates the interferon-responsive pathway. Mol. Cell. Biol. 1999, 19:3607-3613.
96. Bill H.M., Knudsen B., Moores S.L., Muthuswamy S.K., Rao V.R., Brugge J.S., Miranti C.K. Epidermal growth factor receptor-dependent regulation of integrin-mediated signaling and cell cycle entry in epithelial cells. Mol. Cell. Biol. 2004, 24:8586-8599.
97. Widmann C., Gibson S., Jarpe M.B., Johnson G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol. Rev. 1999, 79:143-180.
98. Yurochko A.D., Hwang E.S., Rasmussen L., Keay S., Pereira L., Huang E.S. The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-kappaB during infection. J. Virol. 1997, 71:5051-5059.
99. Yurochko A.D., Huang E.S. Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression. J. Immunol. 1999, 162:4806-4816.
100. Shelbourn S.L., Sissons J.G., Sinclair J.H. Expression of oncogenic ras in human teratocarcinoma cells induces partial differentiation and permissiveness for human cytomegalovirus infection. J. Gen. Virol. 1989, 70(Pt 2):367-374.
101. Johnson R.A., Ma X.L., Yurochko A.D., Huang E.S. The role of MKK1/2 kinase activity in human cytomegalovirus infection. J. Gen. Virol. 2001, 82:493-497.
102. Rodems S.M., Spector D.H. Extracellular signal-regulated kinase activity is sustained early during human cytomegalovirus infection. J. Virol. 1998, 72:9173-9180.
103. Michaelis M., Doerr H.W., Cinatl J. The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia 2009, 11:1-9.
104. Salahuddin S.Z., Ablashi D.V., Markham P.D., Josephs S.F., Sturzenegger S., Kaplan M., Halligan G., Biberfeld P., Wong-Staal F., Kramarsky B., et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 1986, 234:596-601.
105. Braun D.K., Dominguez G., Pellett P.E. Human herpesvirus 6. Clin. Microbiol. Rev. 1997, 10:521-567.
106. Frenkel N., Schirmer E.C., Wyatt L.S., Katsafanas G., Roffman E., Danovich R.M., June C.H. Isolation of a new herpesvirus from human CD4+ T cells. Proc. Natl Acad. Sci. USA 1990, 87:748-752.
107. Santoro F., Kennedy P.E., Locatelli G., Malnati M.S., Berger E.A., Lusso P. CD46 is a cellular receptor for human herpesvirus 6. Cell 1999, 99:817-827.
108. Jarrett R.F., Gledhill S., Qureshi F., Crae S.H., Madhok R., Brown I., Evans I., Krajewski A., O'Brien C.J., Cartwright R.A., et al. Identification of human herpesvirus 6-specific DNA sequences in two patients with non-Hodgkin's lymphoma. Leukemia 1988, 2:496-502.
109. Josephs S.F., Buchbinder A., Streicher H.Z., Ablashi D.V., Salahuddin S.Z., Guo H.G., Wong-Staal F., Cossman J., Raffeld M., Sundeen J., et al. Detection of human B-lymphotropic virus (human herpesvirus 6) sequences in B cell lymphoma tissues of three patients. Leukemia 1988, 2:132-135.
110. Torelli G., Marasca R., Luppi M., Selleri L., Ferrari S., Narni F., Mariano M.T., Federico M., Ceccherini-Nelli L., Bendinelli M., et al. Human herpesvirus-6 in human lymphomas: identification of specific sequences in Hodgkin's lymphomas by polymerase chain reaction. Blood 1991, 77:2251-2258.
111. Araujo J.C., Doniger J., Stoppler H., Sadaie M.R., Rosenthal L.J. Cell lines containing and expressing the human herpesvirus 6A ts gene are protected from both H-ras and BPV-1 transformation. Oncogene 1997, 14:937-943.
112. Araujo J.C., Doniger J., Kashanchi F., Hermonat P.L., Thompson J., Rosenthal L.J. Human herpesvirus 6A ts suppresses both transformation by H-ras and transcription by the H-ras and human immunodeficiency virus type 1 promoters. J. Virol. 1995, 69:4933-4940.
113. Escudero A.L., Luque R.J., Quintero A., Alvarez-Kindelan J., Requena M.J., Montironi R., Lopez-Beltran A. Association of human herpesvirus type 6 DNA with human bladder cancer. Cancer Lett. 2005, 230:20-24.
114. Leite J.L., Stolf H.O., Reis N.A., Ward L.S. Human herpesvirus type 6 and type 1 infection increases susceptibility to nonmelanoma skin tumors. Cancer Lett. 2005, 224:213-219.
115. Martin D., Gutkind J.S. Human tumor-associated viruses and new insights into the molecular mechanisms of cancer. Oncogene 2008, 27(Suppl 2):S31-42.
116. Lambert P.J., Shahrier A.Z., Whitman A.G., Dyson O.F., Reber A.J., McCubrey J.A., Akula S.M. Targeting the PI3K and MAPK pathways to treat Kaposi's-sarcoma-associated herpes virus infection and pathogenesis. Expert. Opin. Ther. Targets 2007, 11:589-599.
117. Rickinson A.B.K., Epstein E. Barr virus. Fields Virol. 2 2001.
118. Kawa K. Epstein-Barr virus-associated diseases in humans. Int. J. Hematol. 2000, 71:108-117.
119. Thorley-Lawson D.A., Babcock G.J. A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells. Life Sci. 1999, 65:1433-1453.
120. Babcock G.J., Hochberg D., Thorley-Lawson A.D. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 2000, 13:497-506.
121. Babcock G.J., Thorley-Lawson D.A. Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc. Natl. Acad Sci. USA 2000, 97:12250-12255.
122. A.C.-F., Arvin G., Mocarski E. Human herpesviruses. Biol., Therapy and immunoprophylaxis 2007, 50.
123. Rowe M., Rowe D.T., Gregory C.D., Young L.S., Farrell P.J., Rupani H., Rickinson A.B. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 1987, 6:2743-2751.
124. Brooks L.A., Lear A.L., Young L.S., Rickinson A.B. Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. J. Virol. 1993, 67:3182-3190.
125. Portis T., Longnecker R. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene 2004, 23:8619-8628.
126. Fukuda M., Longnecker R. Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt Pathway. J. Virol. 2007, 81:9299-9306.
127. Eliopoulos A.G., Young L.S. LMP1 structure and signal transduction. Semin. Cancer Biol. 2001, 11:435-444.
128. Vaysberg M., Hatton O., Lambert S.L., Snow A.L., Wong B., Krams S.M., Martinez O.M. Tumor-derived variants of Epstein-Barr virus latent membrane protein 1 induce sustained Erk activation and c-Fos. J. Biol. Chem. 2008, 283:36573-36585.
129. Roberts M.L., Cooper N.R. Activation of a ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation. Virology 1998, 240:93-99.
130. Dawson C.W., Laverick L., Morris M.A., Tramoutanis G., Young L.S. Epstein-Barr virus-encoded LMP1 regulates epithelial cell motility and invasion via the ERK-MAPK pathway. J Virol 2008, 82:3654-3664.
131. Brinkmann M.M., Schulz T.F. Regulation of intracellular signalling by the terminal membrane proteins of members of the Gammaherpesvirinae. J. Gen. Virol. 2006, 87:1047-1074.
132. Chang Y., Cesarman E., Pessin M.S., Lee F., Culpepper J., Knowles D.M., Moore P.S. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994, 266:1865-1869.
133. Nador R.G., Cesarman E., Chadburn A., Dawson D.B., Ansari M.Q., Sald J., Knowles D.M. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996, 88:645-656.
134. Soulier J., Grollet L., Oksenhendler E., Cacoub P., Cazals-Hatem D., Babinet P., d'Agay M.F., Clauvel J.P., Raphael M., Degos L., et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995, 86:1276-1280.
135. Akula S.M., Pramod N.P., Wang F.Z., Chandran B. Integrin alpha3beta1 (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) entry into the target cells. Cell 2002, 108:407-419.
136. Lagunoff M., Lukac D.M., Ganem D. Immunoreceptor tyrosine-based activation motif-dependent signaling by Kaposi's sarcoma-associated herpesvirus K1 protein: effects on lytic viral replication. J. Virol. 2001, 75:5891-5898.
137. Yu F., Harada J.N., Brown H.J., Deng H., Song M.J., Wu T.T., Kato-Stankiewicz J., Nelson C.G., Vieira J., Tamanoi F., Chanda S.K., Sun R. Systematic identification of cellular signals reactivating Kaposi sarcoma-associated herpesvirus. PLoS Pathog. 2007, 3:e44.
138. Xie J., Ajibade A.O., Ye F., Kuhne K., Gao S.J. Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways. Virology 2008, 371:139-154.
139. Xu Y., AuCoin D.P., Huete A.R., Cei S.A., Hanson L.J., Pari G.S. A Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50 deletion mutant is defective for reactivation of latent virus and DNA replication. J Virol 2005, 79:3479-3487.
140. Lukac D.M., Renne R., Kirshner J.R., Ganem D. Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Virology 1998, 252:304-312.
141. Sun R., Lin S.F., Gradoville L., Yuan Y., Zhu F., Miller G. A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc. Natl. Acad Sci. USA 1998, 95:10866-10871.
142. Pan H., Xie J., Ye F., Gao S.J. Modulation of Kaposi's sarcoma-associated herpesvirus infection and replication by MEK/ERK, JNK, and p38 multiple mitogen-activated protein kinase pathways during primary infection. J. Virol. 2006, 80:5371-5382.
143. Akula S.M., Ford P.W., Whitman A.G., Hamden K.E., Shelton J.G., McCubrey J.A. Raf promotes human herpesvirus-8 (HHV-8/KSHV) infection. Oncogene 2004, 23:5227-5241.
144. Radkov S.A., Kellam P., Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat. Med. 2000, 6:1121-1127.